These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27105443)

  • 1. Economic evaluation of HBV vaccination: A systematic review of recent publications (2000-2013).
    La Torre G; Mannocci A; Saulle R; Colamesta V; Meggiolaro A; Mipatrini D; Sinopoli A
    Hum Vaccin Immunother; 2016 Sep; 12(9):2299-311. PubMed ID: 27105443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluations of hepatitis B vaccination for developing countries.
    Tu HA; Woerdenbag HJ; Kane S; Riewpaiboon A; van Hulst M; Postma MJ
    Expert Rev Vaccines; 2009 Jul; 8(7):907-20. PubMed ID: 19538116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
    Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
    Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients.
    Oddone EZ; Cowper PA; Hamilton JD; Feussner JR
    Health Serv Res; 1993 Apr; 28(1):97-121. PubMed ID: 8463111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy: an a posteriori evaluation and forecast of future benefits.
    Boccalini S; Taddei C; Ceccherini V; Bechini A; Levi M; Bartolozzi D; Bonanni P
    Hum Vaccin Immunother; 2013 May; 9(5):1119-28. PubMed ID: 23376840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: an analytic decision approach to cost-effectiveness.
    Vimolket T; Poovorawan Y
    Southeast Asian J Trop Med Public Health; 2005 May; 36(3):693-9. PubMed ID: 16124440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis.
    Krahn M; Detsky AS
    Med Decis Making; 1993; 13(1):4-20. PubMed ID: 8433635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
    Hung HF; Chen TH
    Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of infant and adolescent hepatitis B vaccination in the UK.
    Siddiqui MR; Gay N; Edmunds WJ; Ramsay M
    Vaccine; 2011 Jan; 29(3):466-75. PubMed ID: 21073988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted outreach hepatitis B vaccination program in high-risk adults: The fundamental challenge of the last mile.
    Mangen MJ; Stibbe H; Urbanus A; Siedenburg EC; Waldhober Q; de Wit GA; van Steenbergen JE;
    Vaccine; 2017 May; 35(24):3215-3221. PubMed ID: 28483198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000).
    Beutels P
    Health Econ; 2001 Dec; 10(8):751-74. PubMed ID: 11747055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of universal newborn hepatitis B vaccination in China.
    Lu SQ; McGhee SM; Xie X; Cheng J; Fielding R
    Vaccine; 2013 Apr; 31(14):1864-9. PubMed ID: 23384752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of economic outcomes of "hepatitis B vaccine event reported by media" in China, 2013].
    Zhang SX; Sun PP; Xia Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Aug; 52(8):837-841. PubMed ID: 30107719
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study.
    Scott N; Palmer A; Morgan C; Lesi O; Spearman CW; Sonderup M; Hellard M
    Lancet Glob Health; 2018 Jun; 6(6):e659-e667. PubMed ID: 29773122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis on economic efficacy regarding previous strategies and current recommendations for vaccination against hepatitis B virus in China].
    Zhang SX; Dang RB; Zhang WD; Liang XF; Cui FQ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Oct; 29(10):1003-8. PubMed ID: 19173882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations.
    Margolis HS; Coleman PJ; Brown RE; Mast EE; Sheingold SH; Arevalo JA
    JAMA; 1995 Oct; 274(15):1201-8. PubMed ID: 7563509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine.
    Kuan RK; Janssen R; Heyward W; Bennett S; Nordyke R
    Vaccine; 2013 Aug; 31(37):4024-32. PubMed ID: 23707166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of hepatitis B screening economic evaluations in low- and middle-income countries.
    Wright CM; Boudarène L; Ha NT; Wu O; Hawkins N
    BMC Public Health; 2018 Mar; 18(1):373. PubMed ID: 29558894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of hepatitis B vaccination of prison inmates.
    Pisu M; Meltzer MI; Lyerla R
    Vaccine; 2002 Dec; 21(3-4):312-21. PubMed ID: 12450707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluations applied to HB vaccination: general observations.
    Beutels P
    Vaccine; 1998 Nov; 16 Suppl():S84-92. PubMed ID: 9915046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.